Skip to main content

AS/Spondyloarthritis

Pollution and Autoimmunity (7.12.2024)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V
Dr. John Cush @RheumNow( View Tweet )
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis? Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk
Dr. John Cush @RheumNow( View Tweet )
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw
Dr. John Cush @RheumNow( View Tweet )

ICYMI: Dead Words Eulogy

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is

Read Article
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab. #EULAR2024

Dr. John Cush @RheumNow( View Tweet )

Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria. https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW
Dr. John Cush @RheumNow( View Tweet )
Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J
Dr. John Cush @RheumNow( View Tweet )
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G
Dr. John Cush @RheumNow( View Tweet )

Future Big BiTEs (6.28.2024)

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
Lit. cohort analysis of >330K #AS shows higher risk of cancer (RR=1.16: 1.07–1.26); w/ higher risk in Asia, but not Europe. Increased CA risk for : bone (RR 3.41), thyroid(1.76), myeloma (1.74), leukemia (1.52), kidney (1.45), prostate (1.43), NHL (1.42) https://t.co/disRefur0l https://t.co/ffjED0Ftvc
Dr. John Cush @RheumNow( View Tweet )
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13
Dr. John Cush @RheumNow( View Tweet )
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024

Dr. John Cush @RheumNow( View Tweet )

In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf

Dr. John Cush @RheumNow( View Tweet )

SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085

Dr. John Cush @RheumNow( View Tweet )

Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg
Dr. John Cush @RheumNow( View Tweet )
Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437 @RheumNow https://t.co/rQ4BunCn6T
Dr. John Cush @RheumNow( View Tweet )
Personalized Exercise may have Key Benefits in AxSpa At EULAR, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for people with AxSpA and severe functional limitations. https://t.co/TUP6hoLgJ4 https://t.co/t1gNQBdFzh
Dr. John Cush @RheumNow( View Tweet )
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8
Dr. John Cush @RheumNow( View Tweet )
Achieving drug-free remission in axSpA In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging. https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P
Dr. John Cush @RheumNow( View Tweet )
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa Retrospective study in French THIN database Diagnostic delay remains common Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain #EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush @RheumNow( View Tweet )

Personalized Exercise may have Key Benefits in Axial Spondyloarthritis

In a very interesting study at #EULAR2024, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for individuals with axial spondyloarthritis (axSpA) and severe functional limitations. This finding marks a critical

Read Article
Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e
Dr. John Cush @RheumNow( View Tweet )
Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
Dr. John Cush @RheumNow( View Tweet )
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. https://t.co/hYy7Wg2GMJ https://t.co/GVjtf89c3t
Dr. John Cush @RheumNow( View Tweet )